In the sensitivity analyses, only minor differences (ranging from 4.0% lower to 1.8% higher) were observed in the pooled prevalence estimates of TET2 gene mutations among cases of MPN compared to the main findings (Table 3 and Figure S7). This evidence concerns the gene TET2 and myeloproliferative disorder.